- Home
- KALA vs COEP Comparison
KALA vs COEP Comparison
Compare KALA & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALA
- COEP
- Stock Information
- Founded
- KALA 2009
- COEP 2017
- Country
- KALA United States
- COEP United States
- Employees
- KALA N/A
- COEP N/A
- Industry
- KALA Biotechnology: Pharmaceutical Preparations
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KALA Health Care
- COEP Health Care
- Exchange
- KALA Nasdaq
- COEP Nasdaq
- Market Cap
- KALA 26.2M
- COEP 27.4M
- IPO Year
- KALA 2017
- COEP N/A
- Fundamental
- Price
- KALA $7.14
- COEP $10.92
- Analyst Decision
- KALA Strong Buy
- COEP
- Analyst Count
- KALA 3
- COEP 0
- Target Price
- KALA $14.00
- COEP N/A
- AVG Volume (30 Days)
- KALA 198.2K
- COEP 55.9K
- Earning Date
- KALA 08-05-2025
- COEP 08-15-2025
- Dividend Yield
- KALA N/A
- COEP N/A
- EPS Growth
- KALA N/A
- COEP N/A
- EPS
- KALA N/A
- COEP N/A
- Revenue
- KALA N/A
- COEP $62,874.00
- Revenue This Year
- KALA N/A
- COEP N/A
- Revenue Next Year
- KALA N/A
- COEP N/A
- P/E Ratio
- KALA N/A
- COEP N/A
- Revenue Growth
- KALA N/A
- COEP N/A
- 52 Week Low
- KALA $2.92
- COEP $2.31
- 52 Week High
- KALA $11.20
- COEP $13.70
- Technical
- Relative Strength Index (RSI)
- KALA 59.52
- COEP 57.24
- Support Level
- KALA $5.35
- COEP $11.30
- Resistance Level
- KALA $8.49
- COEP $12.71
- Average True Range (ATR)
- KALA 0.81
- COEP 0.91
- MACD
- KALA 0.17
- COEP 0.09
- Stochastic Oscillator
- KALA 57.01
- COEP 47.27
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.